| ORIC PHARMACEUTICALS |
| USA |
| Gesundheit |
| US68622P1093 / A2P208 |
| 4TZ (Frankfurt) / ORIC (NASDAQ) |
| FRA:4TZ, ETR:4TZ, 4TZ:GR, NASDAQ:ORIC |
| - |
| https://oricpharma.com/ |
|
Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that address mechanisms of therapeutic resistance in cancer. The company targets innate, acquired, and bypass resistance to overco..
>Volltext.. |
| 649.89 Mio. EUR |
| 416.67 Mio. EUR |
| - |
| -122.83 Mio. EUR |
| -112.16 Mio. EUR |
| -1.31 EUR |
| 6.45 Mio. EUR |
| 39.56 Mio. EUR |
| -98.21 Mio. EUR |
| 13.79 |
| - |
| 10.74% |
| - |
| - |
| - |
| - |
| ORIC PHARMACEUTICALS, ORIC PHARMA, ORIC PHARMACEUTICAL |
| 04.04.26 |
|